GlassScriptPhysician profile
Allison L Smith
NPI 1619403847
$11,027.66
in general payments reported to CMS, 2019-2025
23 companies · $4,110 in 2025
The $4,110 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $800 · 2022: $387 · 2023: $1,503 · 2024: $4,227 · 2025: $4,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,852 · Consulting Fee: $615 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,851.62 |
| Consulting Fee | $615.00 |
| Education | $373.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,449.44 | 2021-2025 | |
| Leo Pharma INC. | $1,360.83 | 2022-2025 | Adbry |
| Genzyme Corporation | $1,274.87 | 2021-2025 | |
| Pfizer INC. | $1,056.38 | 2021-2025 | |
| Incyte Corporation | $981.31 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $752.46 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $630.70 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $598.17 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $507.33 | 2023-2025 | Winlevi |
| Janssen Biotech, INC. | $399.94 | 2023-2025 | Tremfya |
| Amgen INC. | $389.08 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $272.65 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $259.10 | 2024-2025 | Nemluvio |
| Dermavant Sciences, INC. | $196.86 | 2023-2024 | Vtama |
| Organon LLC | $196.09 | 2025 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $173.97 | 2021-2025 | |
| Abbott Laboratories | $157.50 | 2021-2023 | Cardiomems |
| Lilly USA, LLC | $120.25 | 2024 | Olumiant |
| Journey Medical Corporation | $115.97 | 2025 | |
| Almirall LLC | $48.14 | 2021-2025 | Klisyri |
| Horizon Therapeutics Plc | $37.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Boston Scientific Corporation | $18.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.